Sj?gren’s syndrome is an autoimmune disease that classically presents with sicca symptoms and arthralgias, yet a small subset of patients develops central nervous system involvement. We report a 64-year-old woman with Sj?gren’s syndrome (ANA positive, anti-SSA 8) who developed abrupt bilateral lower-extremity and abdominal numbness with back pain and urinary retention. Non-contrast thoracic MRI demonstrated a non-enhancing anterior cord lesion from T3 to T6 consistent with transverse myelitis. Cerebrospinal fluid revealed IgG of 10.1 with an IgG/albumin ratio of 0.31, and negative aquaporin-4 (AQP4) IgG. She received IV methylprednisolone 1 g daily for five days, followed by an oral prednisone taper and inpatient rehabilitation. Hydroxychloroquine was trialed intermittently for sicca symptoms but discontinued due to poor tolerance. Neurology initiated mycophenolate mofetil 500 mg twice daily, later titrated to 1g twice daily, as maintenance therapy; after two years, it was held because of recurrent household viral infections. Over nine months without immunosuppression, her neurologic status remained stable, and catheterization frequency decreased from multiple times daily to every few days, leading to sustained discontinuation of mycophenolate. This AQP4-negative presentation highlights diagnostic uncertainty at the Sj?gren’s syndrome-transverse myelitis interface, the importance of antibody testing beyond AQP4 and the need to balance relapse prevention against infection risk through close rheumatology-neurology coordination and symptom-guided re-imaging.
References
[1]
Negrini, S., Emmi, G., Greco, M., Borro, M., Sardanelli, F., Murdaca, G., et al. (2021) Sjögren’s Syndrome: A Systemic Autoimmune Disease. ClinicalandExperimentalMedicine, 22, 9-25. https://doi.org/10.1007/s10238-021-00728-6
[2]
Zhan, Q., Zhang, J., Lin, Y., Chen, W., Fan, X. and Zhang, D. (2023) Pathogenesis and Treatment of Sjogren’s Syndrome: Review and Update. FrontiersinImmunology, 14, Article 1127417. https://doi.org/10.3389/fimmu.2023.1127417
[3]
Fahad, S., Khan, A., Thapa, P., Khan, M.S., Jogiyat, S., Moustafa, W., et al. (2025) Spectrum of Neurological Complications in Sjögren’s Syndrome: A Comprehensive Review. Cureus, 17, e80092. https://doi.org/10.7759/cureus.80092
[4]
Maleki-Fischbach, M., Kastsianok, L., Koslow, M. and Chan, E.D. (2024) Manifestations and Management of Sjögren’s Disease. ArthritisResearch&Therapy, 26, Article No. 43. https://doi.org/10.1186/s13075-024-03262-4
[5]
Naphade, P., Rohatgi, S., Rao, P. and Nirhale, S. (2024) Sjogren’s Syndrome: A Series of Five Cases. Cureus, 16, e71572. https://doi.org/10.7759/cureus.71572
[6]
Jobling, K., Ledingham, D., Ng, W. and Guadagno, J. (2019) Positive Anti-Mog Antibodies in a Patient with Sjögren’s Syndrome and Transverse Myelitis. EuropeanJournalofRheumatology, 6, 102-104. https://doi.org/10.5152/eurjrheum.2018.18041
[7]
Abbatemarco, J.R., Galli, J.R., Sweeney, M.L., Carlson, N.G., Samara, V.C., Davis, H., et al. (2021) Modern Look at Transverse Myelitis and Inflammatory Myelopathy: Epidemiology of the National Veterans Health Administration Population. NeurologyNeuroimmunology&Neuroinflammation, 8, e1071. https://doi.org/10.1212/nxi.0000000000001071
[8]
Rossel, T., Zekeridou, A., Ochsner, F. and Renaud, S. (2015) Aquaporin-4-Positive Myelitis Associated with Sjögren Syndrome and Colonic Adenocarcinoma. NeurologyNeuroimmunology&Neuroinflammation, 2, e103. https://doi.org/10.1212/nxi.0000000000000103
[9]
Beh, S.C., Greenberg, B.M., Frohman, T. and Frohman, E.M. (2013) Transverse Myelitis. NeurologicClinics, 31, 79-138. https://doi.org/10.1016/j.ncl.2012.09.008
[10]
Prasad, C.B., Kopp, C.R., Naidu, G., Sharma, V., Misra, D.P., Agarwal, V., et al. (2023) Overlap Syndrome of Anti-Aquaporin 4 Positive Neuromyelitis Optica Spectrum Disorder and Primary Sjögren’s Syndrome: A Systematic Review of Individual Patient Data. RheumatologyInternational, 44, 2807-2815. https://doi.org/10.1007/s00296-023-05397-0
[11]
Martín-Nares, E., Hernandez-Molina, G. and Fragoso-Loyo, H. (2019) Aquaporin-4-IgG Positive Neuromyelitis Optica Spectrum Disorder and Systemic Autoimmune Diseases Overlap Syndrome: A Single-Center Experience. Lupus, 28, 1302-1311. https://doi.org/10.1177/0961203319877255
[12]
Jayarangaiah, A., Sehgal, R. and Epperla, N. (2014) Sjögren’s Syndrome and Neuromyelitis Optica Spectrum Disorders (NMOSD)—A Case Report and Review of Literature. BMCNeurology, 14, Article No. 200. https://doi.org/10.1186/s12883-014-0200-5
[13]
Ye, X., Huang, Z., Li, M., Liu, S., Huang, W., Hamud, A.M.S., et al. (2024) Update on Aquaporin-4 Antibody Detection: The Early Diagnosis of Neuromyelitis Optica Spectrum Disorders. MultipleSclerosisandRelatedDisorders, 90, Article ID: 105803. https://doi.org/10.1016/j.msard.2024.105803
[14]
Verkman, A.S., Phuan, P., Asavapanumas, N. and Tradtrantip, L. (2013) Biology of AQP4 and Anti-AQP4 Antibody: Therapeutic Implications for NMO. BrainPathology, 23, 684-695. https://doi.org/10.1111/bpa.12085
[15]
Li, S., Gao, Y., He, Y. and Zhang, Z. (2024) A Case Report of AQP4-IgG-Seropositive Refractory Neuromyelitis Optica Spectrum Disorder Patient with Sjögren’s Syndrome and Pancytopenia Treated with Inebilizumab. FrontiersinNeurology, 15, Article 1371515. https://doi.org/10.3389/fneur.2024.1371515
Xue, Q., Cao, S. and Rui, Q. (2023) Reflections from a NMOSD Case with Serum AQP4-Ab Negativity but CSF Positivity: Narrative Review of How to Interpret AQP4-Ab Test Results. Annals of Translational Medicine, 11, 286-286. https://doi.org/10.21037/atm-20-4110